The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2016 | Re-analysis of RESONATE-2 trial of ibrutinib vs chlorambucil in CLL
Paolo Ghia, MD, PhD of Università Vita-Salute San Raffaele, Milan, Italy, discusses the re-analysis of the RESONATE-2 trial comparing chlorambucil vs ibrutinib as first-line treatment for elderly chronic lymphocytic leukemia (CLL) patients with co-morbidities (NCT01722487). The update shows the data is still consistent with the original results; ibrutinib shows high efficacy and this translates in overall survival (OS). Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
